Abstract: The invention concerns the use of compounds represented by formula (I) as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

Abstract: The invention concerns the use of compounds represented by formula (I) as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

Abstract: The invention concerns the use of compounds represented by formula (I) as inotropic agents. The compounds of formula (1), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

Abstract: The invention concerns the use of compounds represented by formula (I) as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenypethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

Abstract: The present invention relates to a wind turbine component, having a connecting portion for connecting the wind turbine component to another turbine component and at least part of the connecting portion is formed of a first type of metal, characterized in that: the connecting portion is further provided with an additional part formed of a second type of metal which is connected to the metallic part of the connecting portion; and the second type of metal is more active than the first type of metal, whereby the additional part forms a sacrificial anode. The present invention further relates to a wind turbine having the above component.

Abstract: The present invention relates to a wind turbine component, having a connecting portion for connecting the wind turbine component to another turbine component and at least part of the connecting portion is formed of a first type of metal, characterized in that: the connecting portion is further provided with an additional part formed of a second type of metal which is connected to the metallic part of the connecting portion; and the second type of metal is more active than the first type of metal, whereby the additional part forms a sacrificial anode. The present invention further relates to a wind turbine having the above component.

Abstract: Ostomy irrigation sleeve having a tubular shape and a first end with a first opening for receiving ostomy discharge material and a second, opposite end with a second opening for discharge of the ostomy discharge material into a discharge unit, for example a toilet, after guidance through the sleeve. The irrigation sleeve is made of a flexible, water soluble material configured to be water soluble only after a certain time of exposure to liquid, wherein the certain time is at least 3 minutes.

Abstract: Ostomy irrigation sleeve having a tubular shape and a first end with a first opening for receiving ostomy discharge material and a second, opposite end with a second opening for discharge of the ostomy discharge material into a discharge unit, for example a toilet, after guidance through the sleeve. The irrigation sleeve is made of a flexible, water soluble material configured to be water soluble only after a certain time of exposure to liquid, wherein the certain time is at least 3 minutes.